Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Non-Current Assets (2018 - 2025)

BioNexus Gene Lab's Other Non-Current Assets history spans 8 years, with the latest figure at $1.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.6 million for Q4 2025, up 4.22% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 4.22% YoY), and the annual figure for FY2025 was $1.6 million, up 4.22%.
  • Other Non-Current Assets for Q4 2025 was $1.6 million at BioNexus Gene Lab, up from $1.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.3 million in Q1 2024 to a low of $849744.0 in Q2 2022.
  • The 5-year median for Other Non-Current Assets is $1.5 million (2025), against an average of $1.7 million.
  • The sharpest move saw Other Non-Current Assets skyrocketed 245.17% in 2021, then plummeted 54.91% in 2024.
  • Year by year, Other Non-Current Assets stood at $1.5 million in 2021, then fell by 2.48% to $1.5 million in 2022, then soared by 119.33% to $3.3 million in 2023, then plummeted by 54.91% to $1.5 million in 2024, then rose by 4.22% to $1.6 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.6 million, $1.5 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.